KRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment

Modern Pathology

Volumn 25, Issue 5, 2012, Pages 731-739

  Boissière Michot, Florence ^a   Lopez Crapez, Evelyne ^a   Frugier, Hélène ^a   Berthe, Marie Laurence ^b   Ho Pun Cheung, Alexandre ^a   Assenat, Eric ^a   Maudelonde, Thierry ^b   Lamy, Pierre Jean ^a   Bibeau, Frédéric ^a  

^a CENTRE VAL D AURELLE   (France)

^b HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

KRAS; mutation; neoadjuvant treatment; rectal cancer

Indexed keywords

CAPECITABINE; OXALIPLATIN;

ADVANCED CANCER; ALLELE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER RESISTANCE; CHEMORADIOTHERAPY; CONTROLLED STUDY; DNA DETERMINATION; DNA EXTRACTION; DNA SEQUENCE; GENE MUTATION; GENOTYPE; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LASER MICROBEAM MICRODISSECTION; MAJOR CLINICAL STUDY; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECTUM BIOPSY; RECTUM CARCINOMA; RELIABILITY; SEQUENCE ANALYSIS; WILD TYPE;

ADENOCARCINOMA; BIOPSY; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; GENOTYPE; HUMANS; LASER CAPTURE MICRODISSECTION; NEOADJUVANT THERAPY; NEOPLASM, RESIDUAL; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECTAL NEOPLASMS;

EID: 84860463235     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.210     Document Type: Article

References (48)

1. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634.
2. De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008;19: 508-515. (Pubitemid 351325672)
3. Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007;96:1166-1169. (Pubitemid 46625066)
4. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-1765.
5. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007;25:3230-3237. (Pubitemid 47325606)
6. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-3995.
7. Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-379. (Pubitemid 351171687)
8. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009;27:2091-2096.
9. Bellon E, Ligtenberg MJ, Tejpar S, et al. External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds. Oncologist 2011;16:467-478.
10. Plesec TP, Hunt JL. KRAS mutation testing in colorectal cancer. Adv Anat Pathol 2009;16:196-203.
11. van Krieken JH, Jung A, Kirchner T, et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 2008;453:417-431.
12. Jimeno A, Messersmith WA, Hirsch FR, et al. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol 2009; 27:1130-1136.
13. Kobunai T, Watanabe T, Yamamoto Y, Eshima K. The frequency of KRAS mutation detection in human colon carcinoma is influenced by the sensitivity of assay methodology: a comparison between direct sequencing and real-time PCR. Biochem Biophys Res Commun 2010;395:158-162.
14. Oliner K, Juan T, Suggs S, et al. A comparability study of 5 commercial KRAS tests. Diagn Pathol 2010;16:5-23.
15. van Eijk R, van Puijenbroek M, Chhatta AR, et al. Sensitive and specific KRAS somatic mutation analysis on whole-genome amplified DNA from archival tissues. J Mol Diagn 2010;12:27-34.
16. Angulo B, Garcia-Garcia E, Martinez R, et al. A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma. J Mol Diagn 2010;12:292-299.
17. Hunt JL, Finkelstein SD. Microdissection techniques for molecular testing in surgical pathology. Arch Pathol Lab Med 2004;128:1372-1378. (Pubitemid 39627474)
18. Tol J, Dijkstra JR, Vink-Borger ME, et al. High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. J Cell Mol Med 2009;14:2122-2131.
19. Bibeau F, Frugier H, Crapez E, et al. KRAS mutation testing in patients with metastatic colorectal carcinoma: an 18-month experience emphasizing the risk of false-negative results. J Clin Oncol 2010;28:15s (Suppl; abstr 3572).
20. Selves J, Grand D, Guimbaud R, et al. Impact of the amount of tumor cells in tissue samples for detection of KRAS mutations in colorectal cancer. J Clin Oncol 2010;28:15s (Suppl; abstr 3571).
21. Danjoux M, Guimbaud R, Al Saati T, et al. Contribution of microdissection for the detection of microsatellite instability in colorectal cancer. Hum Pathol 2006;37:361-368. (Pubitemid 43277525)
22. Ho-Pun-Cheung A, Assenat E, Bascoul-Mollevi C, et al. A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiation in rectal cancer. Pharmacogenomics J 2011;11:437-443.
23. Ho-Pun-Cheung A, Assenat E, Bascoul-Mollevi C, et al. EGFR and HER3 mRNA expression levels predict distant metastases in locally advanced rectal cancer. Int J Cancer 2011;128:2938-2946.
24. Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997;12:19-23. (Pubitemid 27138353)
25. Lopez-Crapez E, Chypre C, Saavedra J, et al. Rapid and large-scale method to detect K-ras gene mutations in tumor samples. Clin Chem 1997;43:936-942. (Pubitemid 27246982)
26. Lopez-Crapez E, Mineur L, Emptas H, Lamy PJ. KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity? Br J Cancer 2010;102:1074-1075.
27. Weichert W, Schewe C, Lehmann A, et al. KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. J Mol Diagn 2010;12: 35-42.
28. Perspectives on Emerging Technology (POET). Report: KRAS Mutation Testing in Colorectal Cancer (CRCs). College of American Pathologists: Northfield, IL, 2009.
29. Franklin WA, Haney J, Sugita M, et al. KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer. J Mol Diagn 2010;12: 43-50.
30. Bazan V, La Rocca G, Corsale S, et al. Laser pressure catapulting (LPC): optimization LPC-system and genotyping of colorectal carcinomas. J Cell Physiol 2005;202:503-509. (Pubitemid 40041321)
31. Ririe KM, Rasmussen RP, Wittwer CT. Product differentiation by analysis of DNA melting curves during the polymerase chain reaction. Anal Biochem 1997;245: 154-160. (Pubitemid 27082244)
32. Sundstrom M, Edlund K, Lindell M, et al. KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice. BMC Cancer 2010;10:660.
33. Do H, Krypuy M, Mitchell PL, et al. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer 2008;8:142.
34. Cross J. DxS Ltd. Pharmacogenomics 2008;9:463-467.
35. Whitehall V, Tran K, Umapathy A, et al. A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. J Mol Diagn 2009;11:543-552.
36. Garm Spindler KL, Pallisgaard N, Rasmussen AA, et al. The importance of KRAS mutations and EGF61A4G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Ann Oncol 2009;20:879-884.
37. Trusky CL, Sepulveda AR, Hunt JL. Assessment of microsatellite instability in very small microdissected samples and in tumor samples that are contaminated with normal DNA. Diagn Mol Pathol 2006;15:63-69. (Pubitemid 44350481)
38. Akbari M, Hansen MD, Halgunset J, et al. Low copy number DNA template can render polymerase chain reaction error prone in a sequence-dependent manner. J Mol Diagn 2005;7:36-39. (Pubitemid 40310163)
39. Liu Y, Li CM, Lu Z, et al. Studies on formation and repair of formaldehyde-damaged DNA by detection of DNA-protein crosslinks and DNA breaks. Front Biosci 2006;1:991-997. (Pubitemid 43253454)
40. Srinivasan M, Sedmak D, Jewell S. Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol 2002;161:1961-1971. (Pubitemid 35434840)
41. Williams C, Ponten F, Moberg C, et al. A high frequency of sequence alterations is due to formalin fixation of archival specimens. Am J Pathol 1999;155:1467-1471.
42. Lamy A, Blanchard F, Le Pessot F, et al. Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls. Mod Pathol 2011;24:1090-1100.
43. Ondrejka SL, Schaeffer DE, Jakubowski MA, et al. Does neoadjuvant therapy alter KRAS and/or MSI results in rectal adenocarcinoma testing? Am J Surg Pathol 2011; 35:1327-1330.
44. Hughes S, Arneson N, Done S, Squire J. The use of whole genome amplification in the study of human disease. Prog Biophys Mol Biol 2005;88: 173-189. (Pubitemid 39547777)
45. Santini D, Galluzzo S, Gaeta L, et al. Should oncologists be aware in their clinical practice of KRAS molecular analysis? J Clin Oncol 2011;29: e206-e207.
46. Benhaim L, Maley K, Le Corre D, et al. Reply to D. Santini et al. J Clin Oncol 2011;29:e208-e209.
47. Ogino S, Kawasaki T, Brahmandam M, et al. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn 2005;7:413-421. (Pubitemid 41149657)
48. Thomas RK, Nickerson E, Simons JF, et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med 2006;12:852-855. (Pubitemid 44050078)